BridgeBio Pharma, Inc. — Director's Dealing 2020

Nov 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-11-13

Reporting Person: MCCORMICK FRANK (Chairman of Oncology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-13	Common Stock	S	31632	$42.221	Disposed	1268836	Direct
2020-11-13	Common Stock	S	58299	$42.9089	Disposed	1210537	Direct
2020-11-13	Common Stock	S	10069	$43.5682	Disposed	1200468	Direct

Footnotes

F1: Represents the weighted average sale price of the shares sold from $41.53 to $42.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 3 and 4.

F2: Corrects ending balance which was previously overstated by 100 shares in the Reporting Person's Form 4 filings on May 21, 2020 and December 31, 2019.

F3: Represents the weighted average sale price of the shares sold from $42.53 to $43.52 per share.

F4: Represents the weighted average sale price of the shares sold from $43.53 to $43.67 per share.